GMDA News and Press, Gamida Cell Ltd. From 09/29/22

At three years, new data showed overall survival and disease-free survival of 63% and 56% respectively At ten years, follow-up data demonstrated sustained long-term bone marrow recovery Omidubicel patients reported clinically meaningful health-related quality of life s...

Gamida Cell ( NASDAQ: GMDA ) said it signed a commitment letter under which certain funds managed by Highbridge Capital Management committed to provide a $25M senior secured, convertible term loan to the company. The letter does not represent a definitive credit facili...

Gamida Cell ( NASDAQ: GMDA ) has priced a follow-on public offering of 12.91M of its ordinary shares at a public offering price of $1.55/share for aggregate gross proceeds of $20M. Underwriters are granted a 30-day option to purchase up to an additional 1,935,750 ordinary ...

Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Man...

Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public off...

Gamida Cell ( NASDAQ: GMDA ) has launched a follow-on public offering of its shares on Tuesday that is to grant underwriters an overallotment option to purchase an additional 15% of the offering. The Israel-based development stage biopharma firm said it intends t...

Gamida Cell Ltd ( NASDAQ: GMDA ), a biotech focused on cell therapies, announced Monday that Abigail L. Jenkins, who formerly served as the Business Unit Head of Vaccines at contract manufacturer Emergent BioSolutions ( EBS ), has joined the company as Chief Executive. ...

Julian Adams, Ph.D., to Retire and Remain on the Board as Planned Succession Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced th...

- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB) - If approved, Omidubicel is projected to have meaningful improvement in patient outcom...

Today, we circle back on Gamida Cell Ltd., a small developmental company based in Israel for the first time since last November. The company has a key FDA approval pending which could shift the trajectory of the company and the stock. An investment analysis follows in the paragrap...